4SC AG (FRA:VSC) Total Current Assets: €7.82 Mil (As of Dec. 2025)


What is 4SC AG Total Current Assets?

4SC AG FRA:VSC Total Current Assets is €7.82 Mil as of Dec. 2025. The stock has 7 warning signs investors should review.

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. 4SC AG's total current assets for the quarter that ended in Dec. 2025 was €7.82 Mil.


4SC AG  (FRA:VSC) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

4SC AG's Liquidation Value for the quarter that ended in Dec. 2025 is

Liquidation value
= Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=7.572-7.771+0.75 * 0+0.5 * 0
=-0.20

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


4SC AG Total Current Assets Related Terms


4SC AG Total Current Assets Historical Data

* Premium members only.

The historical data trend for 4SC AG's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4SC AG Total Current Assets Chart

4SC AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Current Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 29.53 15.04 8.75 8.73 7.82

4SC AG Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Current Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.75 4.89 8.73 5.68 7.82

4SC AG Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

4SC AG's Total Current Assets for the fiscal year that ended in Dec. 2025 is calculated as

4SC AG's Total Current Assets for the quarter that ended in Dec. 2025 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Frequently Asked Questions Learn more about Total Current Assets →
What does a Total Current Assets of €7.82 Mil mean?
4SC AG (FRA:VSC) has a Total Current Assets of €7.82 Mil as of Dec. 2025. The total amount of assets with liquidity less than one year as recorded on a company's balance sheet. View historical data for 4SC AG and its competitors.
Is 4SC AG's Total Current Assets too high?
4SC AG's current Total Current Assets is €7.82 Mil.
How does 4SC AG's Total Current Assets compare to VRTX and REGN?
4SC AG's Total Current Assets of €7.82 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Current Assets for a Biotechnology company?
A good Total Current Assets depends on the Biotechnology industry context. However, Total Current Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Current Assets mean?
A high Total Current Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets with liquidity less than one year as recorded on a company's balance sheet. View historical data for 4SC AG and its competitors. 4SC AG's current Total Current Assets is €7.82 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 4SC AG stock overvalued right now?
4SC AG (FRA:VSC) has a current Total Current Assets of €7.82 Mil. The stock's GF Value™ is €3.51, compared to a current price of €0.10 — trading 97.2% below its estimated fair value. The current Total Current Assets is €7.82 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Current Assets calculated?
Total Current Assets is calculated from a company's financial statements. For 4SC AG (FRA:VSC), the current Total Current Assets is €7.82 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

4SC AG Business Description

Address Fraunhoferstrasse 22, Planegg-Martinsried, DEU, 82152
4SC AG is a clinical-stage biopharmaceutical company developing small-molecule drugs that can target key indications in cancer with high unmet medical needs. Its pipeline is protected by a comprehensive portfolio of patents and currently comprises two drug candidates in clinical development resminostat and Domatinostat. The geographic area of the company is Germany, the EU, and Other countries, and the majority of the revenue comes from Other Countries.